PPARGC1A and obesity disorder: Furthermore, they also showed that FGF19 was able to protect the skeletal muscle against obesity-induced muscle atrophy through the AMP-activated protein kinase (AMPK)-Sirtuin-1 (SIRT1)-PGC1α pathway, which may be a potential target for obesity treatment [90].